Comparison · NCT00093015-995dd885
Darbepoetin Alfa vs Placebo: Time to All-cause Mortality
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Darbepoetin Alfa vs Placebo: Time to All-cause Mortality. Trial comparisons, record NCT00093015-995dd885. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00093015-995dd885
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.205 | 0.188 | 0.223 | wilson | |
| Risk in group 2 | 0.195 | 0.178 | 0.213 | wilson | |
| Risk difference, group 1 minus group 2 | 0.00981 | -0.0149 | 0.0345 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.05 | 0.928 | 1.19 | log | |
| Odds ratio, group 1 over group 2 | 1.06 | 0.911 | 1.24 | log | |
| Number needed to treat, for one more participant with the outcome on Darbepoetin Alfa than on Placebo | 102 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Darbepoetin Alfa | Subcutaneous darbepoetin alfa at a starting dose of 75 mcg/kg once every 2 weeks, titrated to maintain a hemoglobin concentration of 13.0 g/dL. Dosing was switched to once monthly when two consecutive hemoglobin concentrations between 12.0 and 13.5 g/dL were observed. | 412 | 2,012 | OG001 |
| Group 2 | Placebo | Subcutaneous placebo when hemoglobin concentration was ≥ 9.0 g/dL. Received subcutaneous rescue therapy (once monthly) with darbepoetin alfa in a blinded fashion if the hemoglobin concentration was \<9.0 g/dL until the hemoglobin concentration was ≥ 9.0 g/dL. | 395 | 2,026 | OG000 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Time to All-cause Mortality
- Description
Time from randomization to all-cause mortality. Kaplan-Meier estimate of the median time was not estimable due to low proportion of participants experiencing at least one events, therefore participants experiencing at least one event were summarized.
- Time frame
- Until a primary cardiovascular event (death, myocardial ischemia, congestive heart failure, myocardial infarction or cerebrovascular accident) occurred or 28 March 2009, whichever occurred first
- Population
- The analysis followed intent-to-treat principles. Subjects were analyzed as randomized using all available follow-up information.
Source ClinicalTrials.gov
Trial
- Title
- Trial to Reduce Cardiovascular Events With Aranesp® Therapy (TREAT)
- NCT number
- NCT00093015
- Phases
- PHASE3
- Conditions
- Kidney Disease, Diabetes Mellitus, Anemia
- Interventions
- Placebo, darbepoetin alfa
- Lead sponsor
- Amgen
- Results first posted
- 2010-09-02
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00093015?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00093015-995dd885